Hepatitis B virus (HBV) anti-viral therapy has the potential to reduce the burden of HBV-related liver disease by suppressing HBV deoxyribonucleic acid (DNA) replication to undetectable levels, reducing the progression of liver fibrosis and reducing the risk of hepatocellular carcinoma (HCC) development. Treatment outcomes and long-term benefits require adherence to medication regimens. This study aimed to identify the prevalence and factors associated with non-adherence to anti-viral therapy.